Based on the observation that fucoidan functioned as an adjuvant to activate OVA-specific CD4 and CD8 T cells, we further investigated whether this response can protect mice grafted with OVA-expressing B16 tumor cells. The gene discussed is CD8A; the disease is neoplasm.